Genomic Sequencing in Anatomically Normal Fetuses

Description

This cohort study will examine the clinical utility of genomic sequencing (GS) in patients undergoing prenatal diagnostic procedures (chorionic villus sampling or amniocentesis) for routine indications other than a structural fetal anomaly.

Conditions

Pregnant Individuals Requesting Standard Microarray

Study Overview

Study Details

Study overview

This cohort study will examine the clinical utility of genomic sequencing (GS) in patients undergoing prenatal diagnostic procedures (chorionic villus sampling or amniocentesis) for routine indications other than a structural fetal anomaly.

Genomic Sequencing in Anatomically Normal Fetuses

Genomic Sequencing in Anatomically Normal Fetuses

Condition
Pregnant Individuals Requesting Standard Microarray
Intervention / Treatment

-

Contacts and Locations

San Francisco

University of California, San Francisco, San Francisco, California, United States, 94143

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Pregnant with a structurally normal fetus (singleton or multiple gestation)
  • * Planning to undergo prenatal diagnosis by either chorionic villus sampling or amniocentesis with chromosome microarray analysis for routine indications
  • * Planning, or have already completed expanded carrier screening
  • * Decline prenatal diagnostic testing
  • * Are pregnant and their fetus has a known anomaly
  • * Declined chromosomal microarray analysis of expanded carrier screening

Ages Eligible for Study

18 Years to 64 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

University of California, San Francisco,

Mary Norton, MD, PRINCIPAL_INVESTIGATOR, University of California, San Francisco

Study Record Dates

2030-01